ArticleCardiovascular endocrinology & metabolism2025
BRIDGE-DS study: a multicenter, observational, retrospective analysis of dapagliflozin and sitagliptin combination on modifiable cardiovascular risk factors in T2DM patients with ASCVD or high cardiovascular risk.
Article in Cardiovascular endocrinology & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerotic cardiovascular disease (ASCVD) is a major comorbidity among those with type 2 diabetes mellitus (T2DM) and requires effective management strategies. Few real-world evidence studies have established the safety and efficacy of fixed-dose combinations (FDCs) of dapagliflozin and sitagliptin, specifically in those with T2DM having ASCVD/high cardiovascular risk. The study evaluated the impact of this FDC on glycemic control and the risk of cardiovascular events in those with T2DM and ASCVD or high cardiovascular risk. Methods: This retrospective, multicenter, observational study was conducted on those with T2DM and ASCVD/high cardiovascular risk across India. Data were collected before and after 3 months of treatment with an FDC of dapagliflozin/sitagliptin (10 mg/100 mg). Primary outcomes included alterations in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial glucose (PPG), systolic blood pressure (SBP), cholesterol levels, and the Framingham risk score (FRS). Results: This study included a total of 1091 people with T2DM. Statistically significant ( Conclusion: The dapagliflozin/sitagliptin FDC was effective and safe in managing patients with T2DM with cardiovascular risk factors and may offer cardioprotective benefits. Further investigations with longer follow-ups are necessary to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.